Bone Jack, Baumgarten Sydney, McCarthy Devin G, Bostad William, Richards Douglas L, Gibala Martin J
Department of Kinesiology, McMaster University, Hamilton, Ontario, CANADA.
Department of Medicine, McMaster University, Hamilton, Ontario, CANADA.
Med Sci Sports Exerc. 2025 Jan 1;57(1):163-172. doi: 10.1249/MSS.0000000000003532. Epub 2024 Aug 23.
Twenty-eight adults (16 males and 12 females) aged 30 ± 10 yr (peak oxygen uptake (V̇O 2peak ): 59 ± 11 mL·kg -1 ·min -1 ) completed three experimental trials in a randomized, crossover, and double-blinded manner. Participants ingested either 0.3 (KE-LO) or 0.6 (KE-HI) g·kg -1 body mass of KE or a flavor-matched placebo (PLAC) ~30 min before exercise. Exercise involved a 3-min warm-up, three 5-min stages at fixed incremental workloads corresponding to 75%, 100%, and 125% of individual ventilatory threshold, followed by a ramp protocol to volitional exhaustion to determine peak power output (PPO).
Venous blood [ß-hydroxybutyrate], the major circulating ketone body, was higher after KE ingestion compared with PLAC (KE-HI: 3.0 ± 1.1 ≥ KE-LO: 2.3 ± 0.6 ≥ PLAC: 0.2 ± 0.1 mM; all P ≤ 0.001. There were no differences between conditions in the primary outcome exercise economy, nor gross efficiency or delta efficiency, when analyzed over the entire submaximal exercise period or by stage. Heart rate and ventilation were higher in KE-HI and KE-LO compared with PLAC when assessed over the entire submaximal exercise period and by stage (all P ≤ 0.05). PPO after the ramp was lower in KE-HI compared with both KE-LO and PLAC (329 ± 60 vs 339 ± 62 and 341 ± 61 W, respectively; both P < 0.05) despite no difference in V̇O 2peak .
KE ingestion did not change indices of exercise efficiency but increased markers of cardiorespiratory stress during submaximal incremental cycling and reduced PPO.
28名年龄在30±10岁(峰值摄氧量(V̇O₂peak):59±11 mL·kg⁻¹·min⁻¹)的成年人(16名男性和12名女性)以随机、交叉和双盲的方式完成了三项实验性试验。参与者在运动前约30分钟摄入0.3(KE-LO)或0.6(KE-HI)g·kg⁻¹体重的酮酯(KE)或口味匹配的安慰剂(PLAC)。运动包括3分钟的热身,三个5分钟阶段,以固定的递增工作量对应个体通气阈值的75%、100%和125%,随后进行递增运动至自愿疲劳以确定峰值功率输出(PPO)。
与PLAC相比,摄入KE后静脉血中主要循环酮体[β-羟基丁酸]更高(KE-HI:3.0±1.1≥KE-LO:2.3±0.6≥PLAC:0.2±0.1 mM;所有P≤0.001)。在整个次最大运动期间或按阶段分析时,主要结局运动经济性、总效率或增量效率在各条件之间没有差异。在整个次最大运动期间和按阶段评估时,KE-HI和KE-LO组的心率和通气量均高于PLAC组(所有P≤0.05)。尽管V̇O₂peak没有差异,但KE-HI组在递增运动后的PPO低于KE-LO组和PLAC组(分别为329±60 W、339±62 W和341±61 W;两者P<0.05)。
摄入酮酯不会改变运动效率指标,但会增加次最大递增骑行期间的心肺应激标志物并降低PPO。